Juvenile dermatomyositis: new developments in pathogenesis, assessment and treatment

Best Practice and Research: Clinical Rheumatology

Volumn 23, Issue 5, 2009, Pages 665-678

  Wedderburn, Lucy R ^a   Rider, Lisa G ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

idiopathic inflammatory myopathy (IIM); immunogenetics; juvenile dermatomyositis (JDM); myositis autoantibodies; outcome measures; therapy

Indexed keywords

ALEMTUZUMAB; AUTOANTIBODY; AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ETANERCEPT; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; INFLIXIMAB; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; PREDNISONE; RITUXIMAB; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ABSENCE OF SIDE EFFECTS; ADJUVANT THERAPY; ALOPECIA; AUTOIMMUNE DISEASE; B CELL LYMPHOMA; BIOLOGICAL THERAPY; CARDIOTOXICITY; CATARACT; CLINICAL FEATURE; CLINICAL TRIAL; CORTICOSTEROID THERAPY; DERMATOMYOSITIS; DISEASE ACTIVITY; DRUG BIOAVAILABILITY; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG PULSE THERAPY; DRUG WITHDRAWAL; HERPES ZOSTER; HUMAN; IMMUNOGENETICS; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INCLUSION BODY MYOSITIS; INFECTION; INTESTINE PERFORATION; LYMPHOCYTOPENIA; MUSCLE BIOPSY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOMES RESEARCH; PATHOGENESIS; PHYSIOTHERAPY; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; REVIEW; SIDE EFFECT; STEM CELL TRANSPLANTATION; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT DISEASE; WEIGHT GAIN;

AUTOANTIBODIES; CHILD; DERMATOMYOSITIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS;

EID: 72049106678     PISSN: 15216942     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.berh.2009.07.007     Document Type: Review

References (101)

1. Stringer E., Singh-Grewal D., and Feldman B.M. Predicting the course of juvenile dermatomyositis: significance of early clinical and laboratory features. Arthritis Rheum 58 (2008) 3585-3592
2. Christen-Zaech S., Seshadri R., Sundberg J., et al. Persistent association of nailfold capillaroscopy changes and skin involvement over thirty-six months with duration of untreated disease in patients with juvenile dermatomyositis. Arthritis Rheum 58 (2008) 571-576
3. Symmons D.P., Sills J.A., and Davis S.M. The incidence of juvenile dermatomyositis: results from a nation-wide study. Br J Rheumatol 34 (1995) 732-736
4. Mendez E.P., Lipton R., Ramsey-Goldman R., et al. US incidence of juvenile dermatomyositis, 1995-1998: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Registry. Arthritis Rheum 49 (2003) 300-305
5. McCann L.J., Juggins A.D., Maillard S.M., et al. The Juvenile Dermatomyositis National Registry and Repository (UK and Ireland)-clinical characteristics of children recruited within the first 5 yr. Rheumatology 45 (2006) 1255-1260
6. Wedderburn L.R., and Li C.K. Paediatric idiopathic inflammatory muscle disease. Best Pract Res Clin Rheumatol 18 (2004) 345-358
7. Pachman L.M., Lipton R., Ramsey-Goldman R., et al. History of infection before the onset of juvenile dermatomyositis: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Research Registry. Arthritis Rheum 53 (2005) 166-172
8. Feldman B.M., Rider L.G., Reed A.M., and Pachman L.M. Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood. Lancet 371 (2008) 2201-2212
9. Bohan A., and Peter J.B. Polymyositis and dermatomyositis (two parts). N Engl J Med 292 (1975) 344-347 403-7
10. Maillard S.M., Jones R., Owens C., et al. Quantitative assessment of MRI T2 relaxation time of thigh muscles in juvenile dermatomyositis. Rheumatology 43 (2004) 603-608
11. Brown V.E., Pilkington C.A., Feldman B.M., and Davidson J.E. An international consensus survey of the diagnostic criteria for juvenile dermatomyositis (JDM). Rheumatology 45 (2006) 990-993
12. Wedderburn L.R., Varsani H., Li C.K., et al. International consensus on a proposed score system for muscle biopsy evaluation in patients with juvenile dermatomyositis: a tool for potential use in clinical trials. Arthritis Rheum 57 (2007) 1192-1201
13. Oddis C.V., Rider L.G., Reed A.M., et al. International consensus guidelines for trials of therapies in the idiopathic inflammatory myopathies. Arthritis Rheum 52 (2005) 2607-2615
14. Gregersen P.K., and Olsson L.M. Recent advances in the genetics of autoimmune disease. Annu Rev Immunol 27 (2009) 363-391
15. Constantin T., Ponyi A., Orban I., et al. National registry of patients with juvenile idiopathic inflammatory myopathies in Hungary-clinical characteristics and disease course of 44 patients with juvenile dermatomyositis. Autoimmunity 39 (2006) 223-232
16. Mamyrova G., O'Hanlon T.P., Sillers L., et al. Cytokine gene polymorphisms as risk and severity factors for juvenile dermatomyositis. Arthritis Rheum 58 (2008) 3941-3950
17. Pachman L.M., Jonasson O., Cannon R.A., and Friedman J.M. Increased frequency of HLA-B8 in juvenile dermatomyositis. Lancet 2 (1977) 1238
18. Reed A.M., Pachman L., and Ober C. Molecular genetic studies of major histocompatibility complex genes in children with juvenile dermatomyositis: increased risk associated with HLA-DQA1 *0501. Hum Immunol 32 (1991) 235-240
19. Mamyrova G., O'Hanlon T.P., Monroe J.B., et al. Immunogenetic risk and protective factors for juvenile dermatomyositis in Caucasians. Arthritis Rheum 54 (2006) 3979-3987
20. Wedderburn L.R., McHugh N.J., Chinoy H., et al. HLA class II haplotype and autoantibody associations in children with juvenile dermatomyositis and juvenile dermatomyositis-scleroderma overlap. Rheumatology 46 (2007) 1786-1791
21. Chinoy H, Payne D, Poulton K, et al. HLA-DPB1 associations differ between DRB1*03 positive anti-Jo-1 and anti-PMScl antibody positive idiopathic inflammatory myopathy. Rheumatology, in press, doi:10.1093/rheumatology/kep248.
22. Pachman L.M., Liotta-Davis M.R., Hong D.K., et al. TNFalpha-308A allele in juvenile dermatomyositis: association with increased production of tumor necrosis factor alpha, disease duration, and pathologic calcifications. Arthritis Rheum 43 (2000) 2368-2377
23. Chinoy H., Platt H., Lamb J.A., et al. The protein tyrosine phosphatase N22 gene is associated with juvenile and adult idiopathic inflammatory myopathy independent of the HLA 8.1 haplotype in British Caucasian patients. Arthritis Rheum 58 (2008) 3247-3254
24. O'Hanlon T.P., Rider L.G., Schiffenbauer A., et al. Immunoglobulin gene polymorphisms are susceptibility factors in clinical and autoantibody subgroups of the idiopathic inflammatory myopathies. Arthritis Rheum 58 (2008) 3239-3246
25. Wilson A.G., Symons J.A., McDowell T.L., et al. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci USA 94 (1997) 3195-3199
26. Chinoy H., Salway F., John S., et al. Tumour necrosis factor-alpha single nucleotide polymorphisms are not independent of HLA class I in UK Caucasians with adult onset idiopathic inflammatory myopathies. Rheumatology 46 (2007) 1411-1416
27. Manlhiot C., Liang L., Tran D., et al. Assessment of an infectious disease history preceding juvenile dermatomyositis symptom onset. Rheumatology (Oxford) 47 (2008) 526-529
28. Pachman L.M., Litt D.L., Rowley A.H., et al. Lack of detection of enteroviral RNA or bacterial DNA in magnetic resonance imaging-directed muscle biopsies from twenty children with active untreated juvenile dermatomyositis. Arthritis Rheum 38 (1995) 1513-1518
29. Mamyrova G., Rider L.G., Haagenson L., et al. Parvovirus B19 and onset of juvenile dermatomyositis. JAMA 294 (2005) 2170-2171
30. Vegosen L.J., Weinberg C.R., O'Hanlon T.P., et al. Seasonal birth patterns in myositis subgroups suggest an etiologic role of early environmental exposures. Arthritis Rheum 56 (2007) 2719-2728
31. Rider L.G., and Miller F.W. Classification and treatment of the juvenile idiopathic inflammatory myopathies. Rheum Dis Clin North Am 23 (1997) 619-655
32. Gunawardena H., Betteridge Z., and McHugh N.J. Myositis-specific autoantibodies: their clinical and pathogenic significance in disease expression. Rheumatology 48 (2009) 607-612
33. Feldman B.M., Reichlin M., Laxer R.M., et al. Clinical significance of specific autoantibodies in juvenile dermatomyositis. J Rheumatol 23 (1996) 1794-1797
34. O'Hanlon T.P., Carrick D.M., Targoff I.N., et al. Immunogenetic risk and protective factors for the idiopathic inflammatory myopathies: distinct HLA-A, -B, -Cw, -DRB1, and -DQA1 allelic profiles distinguish European American patients with different myositis autoantibodies. Medicine (Baltimore) 85 (2006) 111-127
35. Targoff I.N., Mamyrova G., Trieu E.P., et al. A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum 54 (2006) 3682-3689
36. Gunawardena H., Wedderburn L.R., North J., et al. Clinical associations of autoantibodies to a p155/140 kDa doublet protein in juvenile dermatomyositis. Rheumatology 47 (2008) 324-328
37. Bingham A., Mamyrova G., Rother K.I., et al. Predictors of acquired lipodystrophy in juvenile-onset dermatomyositis and a gradient of severity. Medicine (Baltimore) 87 (2008) 70-86
38. Gunawardena H., Wedderburn L.R., Chinoy H., et al. Autoantibodies to a 140-kd protein in juvenile dermatomyositis are associated with calcinosis. Arthritis Rheum 60 (2009) 1807-1814
39. Casciola-Rosen L., Nagaraju K., Plotz P., et al. Enhanced autoantigen expression in regenerating muscle cells in idiopathic inflammatory myopathy. J Exp Med 201 (2005) 591-601
40. Howard O.M., Dong H.F., Yang D., et al. Histidyl-tRNA synthetase and asparaginyl-tRNA synthetase, autoantigens in myositis, activate chemokine receptors on T lymphocytes and immature dendritic cells. J Exp Med 196 (2002) 781-791
41. Eloranta M.L., Barbasso Helmers S., Ulfgren A.K., et al. A possible mechanism for endogenous activation of the type I interferon system in myositis patients with anti-Jo-1 or anti-Ro 52/anti-Ro 60 autoantibodies. Arthritis Rheum 56 (2007) 3112-3124
42. Tezak Z., Hoffman E.P., Lutz J.L., et al. Gene expression profiling in DQA1*0501+ children with untreated dermatomyositis: a novel model of pathogenesis. J Immunol 168 (2002) 4154-4163
43. O'Connor K.A., Abbott K.A., Sabin B., et al. MxA gene expression in juvenile dermatomyositis peripheral blood mononuclear cells: association with muscle involvement. Clin Immunol 120 (2006) 319-325
44. Miles L., Bove K.E., Lovell D., et al. Predictability of the clinical course of juvenile dermatomyositis based on initial muscle biopsy: a retrospective study of 72 patients. Arthritis Rheum 57 (2007) 1183-1191
45. Emslie-Smith A.M., and Engel A.G. Microvascular changes in early and advanced dermatomyositis: a quantitative study. Ann Neurol 27 (1990) 343-356
46. Lundberg I., Ulfgren A.K., Nyberg P., et al. Cytokine production in muscle tissue of patients with idiopathic inflammatory myopathies. Arthritis Rheum 40 (1997) 865-874
47. Sallum A.M., Marie S.K., Wakamatsu A., et al. Immunohistochemical analysis of adhesion molecule expression on muscle biopsy specimens from patients with juvenile dermatomyositis. J Rheumatol 31 (2004) 801-807
48. Fall N., Bove K.E., Stringer K., et al. Association between lack of angiogenic response in muscle tissue and high expression of angiostatic ELR-negative CXC chemokines in patients with juvenile dermatomyositis: possible link to vasculopathy. Arthritis Rheum 52 (2005) 3175-3180
49. Nagaraju K., Rider L.G., Fan C., et al. Endothelial cell activation and neovascularization are prominent in dermatomyositis. J Autoimmune Dis 3 (2006) 2
50. Baechler E.C., Bauer J.W., Slattery C.A., et al. An interferon signature in the peripheral blood of dermatomyositis patients is associated with disease activity. Mol Med 13 (2007) 59-68
51. Lopez de Padilla C.M., Vallejo A.N., McNallan K.T., et al. Plasmacytoid dendritic cells in inflamed muscle of patients with juvenile dermatomyositis. Arthritis Rheum 56 (2007) 1658-1668
52. Lopez De Padilla C.M., Vallejo A.N., Lacomis D., et al. Extranodal lymphoid microstructures in inflamed muscle and disease severity of new-onset juvenile dermatomyositis. Arthritis Rheum 60 (2009) 1160-1172
53. Reed A.M., McNallan K., Wettstein P., et al. Does HLA-dependent chimerism underlie the pathogenesis of juvenile dermatomyositis?. J Immunol 172 (2004) 5041-5046
54. Li C.K., Varsani H., Holton J.L., et al. MHC Class I overexpression on muscles in early juvenile dermatomyositis. J Rheumatol 31 (2004) 605-609
55. Nagaraju K., Raben N., Loeffler L., et al. Conditional up-regulation of MHC class I in skeletal muscle leads to self-sustaining autoimmune myositis and myositis-specific autoantibodies. Proc Natl Acad Sci USA 97 (2000) 9209-9214
56. Salomonsson S., Grundtman C., Zhang S.J., et al. Upregulation of MHC class I in transgenic mice results in reduced force-generating capacity in slow-twitch muscle. Muscle Nerve 39 (2009) 674-682
57. Li C, Knopp P, Moncrieffe H, et al. Over expression of MHC class l heavy chain protein in young skeletal muscle leads to severe myositis: implications for juvenile myositis. Am J Pathol, in press, doi:10.2353/ajpath.2009.090196.
58. Miller F.W., Rider L.G., Chung Y.L., et al. Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies. Rheumatology 40 (2001) 1262-1273
59. Ruperto N., Ravelli A., Murray K.J., et al. Preliminary core sets of measures for disease activity and damage assessment in juvenile systemic lupus erythematosus and juvenile dermatomyositis. Rheumatology 42 (2003) 1452-1459
60. Ruperto N., Ravelli A., Pistorio A., et al. The provisional Paediatric Rheumatology International Trials Organisation/American College of Rheumatology/European League Against Rheumatism Disease activity core set for the evaluation of response to therapy in juvenile dermatomyositis: a prospective validation study. Arthritis Rheum 59 (2008) 4-13
61. Rider L.G., Giannini E.H., Brunner H.I., et al. International consensus on preliminary definitions of improvement in adult and juvenile myositis. Arthritis Rheum 50 (2004) 2281-2290
62. Ruperto N., Woo P., Cuttica R., et al. The validated PRINTO core set and definition of improvement for juvenile myositis. Arthritis Rheum 50 S (2004) S534
63. Ravelli A., Ruperto N., Trail L., et al. Clinical assessment in juvenile dermatomyositis. Autoimmunity 39 (2006) 197-203
64. Huber A.M., Dugan E.M., Lachenbruch P.A., et al. The Cutaneous Assessment Tool: development and reliability in juvenile idiopathic inflammatory myopathy. Rheumatology 46 (2007) 1606-1611
65. Huber A.M., Dugan E.M., Lachenbruch P.A., et al. Preliminary validation and clinical meaning of the Cutaneous Assessment Tool in juvenile dermatomyositis. Arthritis Rheum 59 (2008) 214-221
66. Huber A.M., Lachenbruch P.A., Dugan E.M., et al. Alternative scoring of the Cutaneous Assessment Tool in juvenile dermatomyositis: results using abbreviated formats. Arthritis Rheum 59 (2008) 352-356
67. Dugan E.M., Huber A.M., Miller F.W., and Rider L.G. Photoessay of the cutaneous manifestations of the idiopathic inflammatory myopathies. Dermatol Online J 15 (2009) 1
68. Bode R.K., Klein-Gitelman M.S., Miller M.L., et al. Disease activity score for children with juvenile dermatomyositis: reliability and validity evidence. Arthritis Rheum 49 (2003) 7-15
69. Smith R.L., Sundberg J., Shamiyah E., et al. Skin involvement in juvenile dermatomyositis is associated with loss of end row nailfold capillary loops. J Rheumatol 31 (2004) 1644-1649
70. Rouster-Stevens K.A., Gursahaney A., Ngai K.L., et al. Pharmacokinetic study of oral prednisolone compared with intravenous methylprednisolone in patients with juvenile dermatomyositis. Arthritis Rheum 59 (2008) 222-226
71. Carroll C.L., Lang W., Snively B., et al. Development and validation of the Dermatomyositis Skin Severity Index. Br J Dermatol 158 (2008) 345-350
72. Klein R.Q., Bangert C.A., Costner M., et al. Comparison of the reliability and validity of outcome instruments for cutaneous dermatomyositis. Br J Dermatol 159 (2008) 887-894
73. Apaz M.T., Saad-Magalhaes C., Pistorio A., et al. Health-related quality of life of patients with juvenile dermatomyositis: results from the Pediatric Rheumatology International Trials Organisation multinational quality of life cohort study. Arthritis Rheum 61 (2009) 509-517
74. Rider LG, Lachenbruch PA, Monroe JB, et al. Damage extent and predictors in adult and juvenile dermatomyositis and polymyositis using the myositis damage index. Arthritis Rheum, in press.
75. Traill L., Ruperto N., Pilkington C.A., et al. The long-term outcome of juvenile idiopathic inflammatory myopathies: a multicenter, multinational study of 557 patients. Arthritis Rheum 52 (2007) S830
76. Sanner H., Gran J.T., Sjaastad I., and Flato B. Organ damage and prognostic factors in juvenile dermatomyositis. Ann Rheum Dis 68 Suppl (2009) S500
77. McCann L.J., Garay S.M., Ryan M.M., et al. Oropharyngeal dysphagia in juvenile dermatomyositis (JDM): an evaluation of videofluoroscopy swallow study (VFSS) changes in relation to clinical symptoms and objective muscle scores. Rheumatology 46 (2007) 1363-1366
78. Coyle K, Rother KI, Weise M, et al. Metabolic abnormalities and cardiovascular risk factors in children with myositis. J Paediatrics, in press, doi:10.2353/ajpath.2009.090196.
79. Kimball A.B., Summers R.M., Turner M., et al. Magnetic resonance imaging detection of occult skin and subcutaneous abnormalities in juvenile dermatomyositis. Implications for diagnosis and therapy. Arthritis Rheum 43 (2000) 1866-1873
80. Rider L.G. Outcome assessment in the adult and juvenile idiopathic inflammatory myopathies. Rheum Dis Clin North Am 28 (2002) 935-977
81. Bilgic H., Ytterberg S.R., McNallan K.T., et al. IL-17 and IFN-regulated genes and chemokines as biomarkers of disease activity in inflammatory myopathies. Arthritis Rheum 58 (2008) S922
82. Zipitis C.S., Baildam E.M., and Ramanan A.V. Treatment approaches to juvenile dermatomyositis. Expert Opin Pharmacother 5 (2004) 1509-1515
83. Maillard S.M., Jones R., Owens C.M., et al. Quantitative assessments of the effects of a single exercise session on muscles in juvenile dermatomyositis. Arthritis Rheum 53 (2005) 558-564
84. Pilkington C.A., and Wedderburn L.R. Paediatric idiopathic inflammatory muscle disease: recognition and management. Drugs 65 (2005) 1355-1365
85. Kim S., El-Hallak M., Dedeoglu F., et al. Complete and sustained remission of juvenile dermatomyositis resulting from aggressive treatment. Arthritis Rheum 60 (2009) 1825-1830
86. Ramanan A.V., Campbell-Webster N., Ota S., et al. The effectiveness of treating juvenile dermatomyositis with methotrexate and aggressively tapered corticosteroids. Arthritis Rheum 52 (2005) 3570-3578
87. Seshadri R., Feldman B.M., Ilowite N., et al. The role of aggressive corticosteroid therapy in patients with juvenile dermatomyositis: a propensity score analysis. Arthritis Rheum 59 (2008) 989-995
88. Riley P., Maillard S.M., Wedderburn L.R., et al. Intravenous cyclophosphamide pulse therapy in juvenile dermatomyositis. A review of efficacy and safety. Rheumatology 43 (2004) 491-496
89. Majithia V., and Harisdangkul V. Mycophenolate mofetil (CellCept): an alternative therapy for autoimmune inflammatory myopathy. Rheumatology 44 (2005) 386-389
90. Rouster-Stevens K.A., and Pachman L. Mycophenolate mofetil in juvenile dermatomyositis. Arthritis Rheum 54 (2006) S680
91. Oddis C.V., Sciurba F.C., Elmagd K.A., and Starzl T.E. Tacrolimus in refractory polymyositis with interstitial lung disease. Lancet 353 (1999) 1762-1763
92. Hassan J., van der Net J.J., and van Royen-Kerkhof A. Treatment of refractory juvenile dermatomyositis with tacrolimus. Clin Rheumatol 27 (2008) 1469-1471
93. Levine T.D. Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum 52 (2005) 601-607
94. Cooper M.A., Willingham D.L., Brown D.E., et al. Rituximab for the treatment of juvenile dermatomyositis: a report of four pediatric patients. Arthritis Rheum 56 (2007) 3107-3111
95. Chung L., Genovese M.C., and Fiorentino D.F. A pilot trial of rituximab in the treatment of patients with dermatomyositis. Arch Dermatol 143 (2007) 763-767
96. Ram R., Ben-Bassat I., Shpilberg O., et al. The late adverse events of rituximab therapy-rare but there!. Leuk Lymphoma 50 (2009) 1083-1095
97. Riley P., McCann L.J., Maillard S.M., et al. Effectiveness of infliximab in the treatment of refractory juvenile dermatomyositis with calcinosis. Rheumatology 47 (2008) 877-880
98. Miller M.L., Smith R., Abbott K.A., et al. Use of Etanercept in chronic juvenile dermatomyositis. Arthritis Rheum 44 Supplement (2002) S306
99. Dastmalchi M., Grundtman C., Alexanderson H., et al. A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies. Ann Rheum Dis 67 (2008) 1670-1677
100. Holzer U, van Royen-Kerkhof, van der Torre P, et al. Successful autologous stem cell transplantation in two patients with juvenile dermatomyositis. Scandinavian Journal of Rheumatology, in press, doi:10.1080/03009740903096622
101. Rider L.G. The heterogeneity of juvenile myositis. Autoimmun Rev 6 (2007) 241-247